ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Neoplasm Metastasis
Breast Cancer
Squamous Cell Carcinoma of Head and Neck

Lung Cancer trials near Portland, OR, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Portland, Oregon, United States and 72 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Portland, Oregon, United States and 124 other locations

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Vancouver, Washington, United States and 58 other locations

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung...

Enrolling
Small Cell Lung Cancer
Drug: Amrubicin
Drug: Lurbinectedin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Portland, Oregon, United States and 233 other locations

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein lig...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: pemetrexed
Drug: Tislelizumab

Phase 2

BeiGene
BeiGene

Portland, Oregon, United States and 61 other locations

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Alectinib

Phase 2

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 46 other locations

Locations recently updated

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sit...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

AbbVie
AbbVie

Portland, Oregon, United States and 71 other locations

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung...

Active, not recruiting
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Sotorasib
Drug: Divarasib

Phase 3

Roche
Roche

Portland, Oregon, United States and 156 other locations

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 182 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the ...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Salem, Oregon, United States and 327 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems